As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Translational Development Acquisition Corp. The largest reported stake is The Goldman Sachs Group, Inc.'s, at 7.2%. 9 filings are on record since July 11, 2025 (Schedule 13G/A, August 12, 2026).
Sell to companies like Translational Development Acquisition Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Linden Capital L.P. · Sole voting: 0 · Shared voting: 1,109,668 · Sole dispositive: 0 · Shared dispositive: 1,109,668 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Meteora Capital, LLC · Sole voting: 0 · Shared voting: 919,000 · Sole dispositive: 0 · Shared dispositive: 919,000 · SCHEDULE 13G, 2026-08-14
- · Reporting person: The Goldman Sachs Group, Inc. · Sole voting: 0 · Shared voting: 1,056,879 · Sole dispositive: 0 · Shared dispositive: 1,056,879 · SCHEDULE 13G/A, 2026-08-12
- · Reporting person: Wolverine Asset Management, LLC · Sole voting: 0 · Shared voting: 944,878 · Sole dispositive: 0 · Shared dispositive: 944,878 · SCHEDULE 13G/A, 2026-07-16
- · Holder: Linden Advisors LP · Percent: 5.5% · SCHEDULE 13G
Translational Development Acquisition Corp. has 9 Schedule 13D or 13G filings on record since 2025-07-11. 3 holders' latest filing reports 5% or more of class a common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| The Goldman Sachs Group, Inc. | 7.2% | 1,056,879 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| Linden Advisors LP | 6.7% | 1,150,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Meteora Capital, LLC | 6.27% | 919,000 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Wolverine Asset Management, LLC | 4.89% | 944,878 | SCHEDULE 13G/A, 2026-07-16 | 2026-06-30 |
| Bank of Montreal | 4.64% | 800,000 | SCHEDULE 13G/A, 2025-07-31 | 2025-06-30 |
Holding shares or following this stake? See who's behind Translational Development Acquisition Corp. and the warning signs.
Free to see. No signup.
Keep reading
More on Translational Development Acquisition Corp. and the records around it.
Companies that share a holder
- Bank of Montreal also filed stake reports on 49 other companies: Akari Therapeutics Plc (Aug 2026), Alarm.com Holdings, Inc. (Aug 2026), North American Construction Group Ltd. (Aug 2026)
- Linden Capital L.P. also filed stake reports on 73 other companies: Southport Acquisition Corp. II (Oct 2026), NewHold Investment Corp IV (Sep 2026), Haymaker Acquisition Corp V (Sep 2026)
- WOLVERINE ASSET MANAGEMENT LLC also filed stake reports on 75 other companies: Black Hawk Acquisition Corp (Nov 2026), AmperCap Acquisition Company (Oct 2026), BTC Development Corp. (Oct 2026)
Watch Translational Development Acquisition Corp.
Get an email when Translational Development Acquisition Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Translational Development Acquisition Corp.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Translational Development Acquisition Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Translational Development Acquisition Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| The Goldman Sachs Group, Inc. | 0 | 1,056,879 | 0 | 1,056,879 | SCHEDULE 13G/A, 2026-08-12 |
| Goldman Sachs & Co. LLC | 0 | 1,056,879 | 0 | 1,056,879 | SCHEDULE 13G/A, 2026-08-12 |
| Linden Capital L.P. | 0 | 1,109,668 | 0 | 1,109,668 | SCHEDULE 13G/A, 2026-08-14 |
| Linden GP LLC | 0 | 1,109,668 | 0 | 1,109,668 | SCHEDULE 13G/A, 2026-08-14 |
| Linden Advisors LP | 0 | 1,150,000 | 0 | 1,150,000 | SCHEDULE 13G/A, 2026-08-14 |
| Siu Min Wong | 0 | 1,150,000 | 0 | 1,150,000 | SCHEDULE 13G/A, 2026-08-14 |
| Meteora Capital, LLC | 0 | 919,000 | 0 | 919,000 | SCHEDULE 13G, 2026-08-14 |
| Wolverine Asset Management, LLC | 0 | 944,878 | 0 | 944,878 | SCHEDULE 13G/A, 2026-07-16 |
| Wolverine Holdings, LLC | 0 | 944,878 | 0 | 944,878 | SCHEDULE 13G/A, 2026-07-16 |
| Christopher L. Gust | 0 | 944,878 | 0 | 944,878 | SCHEDULE 13G/A, 2026-07-16 |
| Robert R. Bellick | 0 | 944,878 | 0 | 944,878 | SCHEDULE 13G/A, 2026-07-16 |
The latest filing identifies Translational Development Acquisition Corp. by CUSIP G9008W105 and gives its principal executive office as 52 E. 83rd Street, New York, NY 10028 (SCHEDULE 13G/A, 2026-08-14).
What the percentages are based on
WAM may be deemed the beneficial owner of 4.89% of the Issuer's outstanding Class A Ordinary Shares and each of Wolverine Holdings, Mr. Bellick, and Mr. Gust may be deemed the beneficial owner of 4.89% of the Issuer's outstanding Class A Ordinary Shares.Wolverine Asset Management, LLC, SCHEDULE 13G/A, 2026-07-16
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-11 | Wolverine Asset Management LLC | 7.85% | SCHEDULE 13G/A |
| 2025-07-31 | Bank of Montreal | 4.64% | SCHEDULE 13G/A |
| 2025-10-10 | Wolverine Asset Management LLC | 9.03% | SCHEDULE 13G/A |
| 2026-05-13 | The Goldman Sachs Group, Inc. | 6.1% | SCHEDULE 13G |
| 2026-06-02 | Linden Advisors LP | 5.5% | SCHEDULE 13G |
| 2026-07-16 | Wolverine Asset Management, LLC | 4.89% | SCHEDULE 13G/A |
| 2026-08-12 | The Goldman Sachs Group, Inc. | 7.2% | SCHEDULE 13G/A |
| 2026-08-14 | Linden Advisors LP | 6.7% | SCHEDULE 13G/A |
| 2026-08-14 | Meteora Capital, LLC | 6.27% | SCHEDULE 13G |
Questions about who owns Translational Development Acquisition Corp.
Who owns Translational Development Acquisition Corp.?
On this page, 3 holders' latest ownership filings report 5% or more of Translational Development Acquisition Corp.: The Goldman Sachs Group, Inc. (7.2%, Schedule 13G/A, filed 2026-08-12), Linden Advisors LP (6.7%, Schedule 13G/A, filed 2026-08-14) and Meteora Capital, LLC (6.27%, Schedule 13G, filed 2026-08-14).
Who are the largest shareholders of Translational Development Acquisition Corp.?
By the share each holder's latest filing reports, the largest holders of Translational Development Acquisition Corp. on this page are The Goldman Sachs Group, Inc. (7.2%), Linden Advisors LP (6.7%) and Meteora Capital, LLC (6.27%).
When did The Goldman Sachs Group, Inc. buy into Translational Development Acquisition Corp.?
The filings give report dates, not purchase dates. The earliest filing from The Goldman Sachs Group, Inc. on this page is the Schedule 13G, filed 2026-05-13, reporting 6.1%; its latest, Schedule 13G/A filed 2026-08-12, reports 7.2%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Translational Development Acquisition Corp.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| December 23, 2024 | IPO filing, Form 424B4 | — | IPO filings | Source |
| December 19, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
| November 20, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
| October 22, 2024 | IPO filing, Form S-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for Translational Development Acquisition Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.